Mira Pharmaceuticals Inc. has reported results from preclinical studies evaluating an optimized oral formulation of SKNY-1, an oral drug candidate being developed for obesity and addiction-related disorders.
Metachromatic leukodystrophy (MLD) is a rare inherited lysosomal storage disorder characterized by progressive neurodegeneration resulting from loss of arylsulfatase A (ARSA) activity. Researchers at Kazan Federal University reported preclinical efficacy data for a gene therapy candidate in a porcine model of MLD.
Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million).
Vertex Pharmaceuticals Inc. is buying Crinetics Pharmaceuticals Inc. for $85 per share in cash, which translates to about $10 billion in equity value. Both boards approved the transaction, expected to close in the third quarter of 2026.
Ascletis Pharma Inc. has submitted two IND applications to the FDA for ASC-36 once-monthly injection and ASC-36_35 once-monthly injection co-formulation for the treatment of obesity.
Brightgene Bio-Medical Technology Co. Ltd. has patented new calcitonin receptor (CALCR; CT-R) and amylin AMY3 receptor agonists potentially useful for the treatment of obesity and metabolic disorders.
FAM3D is a protein mainly expressed in the gastrointestinal tract, but also detectable in vascular endothelial cells. It is known to worsen intestinal inflammation by recruiting neutrophils, but its role in atherosclerosis is not well understood.
Ribocure Pharmaceuticals AB, a subsidiary of Suzhou Ribo Life Science Co. Ltd., and Madrigal Pharmaceuticals Inc. have achieved the first drug candidate nomination within their siRNA partnership.
Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million).
Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results.
RSS
